A review of clinical and molecular evidence suggests the endocannabinoid system may play a role in bipolar disorder, with CB2 receptor activation emerging as a potential mood-stabilizing target.
Bipolar disorder researchers, psychiatrists exploring novel treatment targets, and patients interested in the biology of mood regulation.
CB2 receptors as mood target
What the researchers found
The endocannabinoid system exerts neuromodulatory effects on neurotransmitter systems critical for emotion regulation. Limited clinical and molecular evidence suggests ECS dysfunction may contribute to bipolar disorder pathophysiology, with selective CB2 receptor agonists showing potential for mood stabilization.
Why it matters
Bipolar disorder remains inadequately treated in a significant subset of patients. If ECS manipulation can stabilize mood, it would open an entirely new class of treatment targets for a condition with limited pharmacological options.
The numbers in context
No specific numerical outcomes reported. The review highlights that the ECS role in BD has been "almost neglected" in research despite available data suggesting mood regulation involvement.
How the study worked
Perspective review synthesizing clinical, molecular, and anecdotal evidence on the relationship between the endocannabinoid system and bipolar disorder.
What this study cannot tell us
The available data on ECS and bipolar disorder is very limited. The CB2 mood stabilization hypothesis is based on indirect evidence rather than clinical trials. Cannabis use in BD also carries risks including triggering manic episodes.
How to read the evidence
Rated preliminary because the evidence linking the ECS to bipolar disorder is mostly indirect and no clinical trials of cannabinoid-based BD treatments have been conducted.
When this study was published
Published in 2019. Research on endocannabinoid involvement in mood disorders has continued to develop.
The bigger picture
Cannabis use is common among people with bipolar disorder, often as self-medication. Understanding the ECS-mood connection could explain both the appeal and the risks of cannabis use in this population, and potentially lead to targeted cannabinoid therapies.
Questions still open
- Could selective CB2 agonists stabilize mood without the risks associated with cannabis use? What are the specific ECS alterations in bipolar disorder versus healthy controls? Would targeting the ECS help treatment-resistant BD patients?
Common questions
Does cannabis help bipolar disorder?
What is the CB2 receptor hypothesis?
Read the original research
Bipolar disorder and the endocannabinoid system.
Acta neuropsychiatrica, 31(4), 193-201
Citation
Arjmand, Shokouh; Behzadi, Mina; Kohlmeier, Kristi A; Mazhari, Shahrzad; Sabahi, Abdolreza; Shabani, Mohammad. (2019). Bipolar disorder and the endocannabinoid system.. Acta neuropsychiatrica, 31(4), 193-201. https://doi.org/10.1017/neu.2019.21
Explore the wider topic
- LGBTQ+ and Cannabis: Higher Use Rates and Recovery
- Cannabis-Induced Psychosis: What It Is, Who's at Risk, and What to Do
- BetterHelp, Cerebral, and Online Therapy: Honest Review
- Quitting Weed with ADHD: Why It Is Harder and What Actually Helps
- Quitting Weed with Depression: What You Need to Know
- Quitting Weed with PTSD: A Practical Guide
- Self-Medicating with Weed: Why It Works Until It Doesn't
- Weed and OCD: Self-Medicating Intrusive Thoughts
- Weed and PTSD: What the Research Actually Shows
- Weed and Childhood Trauma: ACEs, Self-Medication, and the Path to Real Healing
- Weed and Suicidal Thoughts: What You Need to Know